


CIPAC STATUS REPORT

25.07.2025



1029 Flumetnicam (4-(trifluoromethyl)-nicotinamide)

Allocated to DAPA

CIPAC methods published in: CIPAC Handbook -

CIPAC

CIPAC 68th meeting, June 2024 Wageningen

4-(trifluoromethyl)-nicotinamide by Mr Christian Mink (5368, 5369)

Mr Christian Mink presented the results of a small scale collaborative trial of 4-(trifluoromethyl)-nicotinamide of five TC samples in which five DAPA laboratories participated. Two Syngenta laboratories analysed and reported results twice which totalled to seven available results for statistical review. Unfortunately, sample E was lost at a laboratory, so for sample E only six results were available. The analysis was performed by RP-HPLC using UV detection at 265 nm and external standardization. A Kinetex Polar C18 column was used (Phenomenex, 150 × 4.6 mm, 2.6 µm) at 30°C and an acetonitril/water + 0.5% H₃PO₄ gradient was applied. Five results were obtained with the prescribed HPLC column, two results were obtained with a comparable HPLC column and all laboratories returned results in due time. During statistical evaluation no stragglers or outliers were identified. The HorRat values of the five TC samples were between 0.2 and 0.3 therefore fulfilling the test criteria.

Mr Christian Mink recommended to go for a full scale CIPAC collaborative trial.

No comments of the meeting were received.

Closed meeting:

No comments were given or questions were asked by the meeting. The method can proceed to full scale trial.

CIPAC STATUS REPORT

25.07.2025

CIPAC 69th meeting, June 2025 Galway

Flumetnicam by Mr Christian Mink (5402, 5403)

Mr Christian Mink presented the results of a full scale collaborative trial of flumetnicam of five TC samples (A to E) in which eleven laboratories the EU, USA and Asia participated. All laboratories reported results in time. Nine laboratories followed the proposed analytical method whereas two laboratories used a different HPLC column. The deviations were assessed as non-critical. Three different statistical approaches were applied. One in which all data were used, one in which only the data were used of the laboratories who followed exactly the proposed method and finally one in which a statistical straggler was excluded. With all data included HorRat values ranged from 0.24 to 0.34. When removing one straggler the achieved HorRat values ranged from 0.24 to 0.31. The HorRat values of the data of the laboratories who followed exactly the proposed method were not presented. Syngenta considers this method to be suitable for the intended purpose and recommends accepting it as a provisional CIPAC method for the determination of Flumetnicam TC.

Questions and remarks from the meeting.

- No questions or remarks were asked or given

Closed Meeting:

The reversed phase HPLC method (CIPAC/5402) for the determination of flumetnicam in TC formulations was accepted as **provisional** CIPAC method